Work

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question—Reply

Year: 2016

Type: article

Source: JAMA Oncology

DOI: 10.1001/jamaoncol.2016.3947

Author: Donald A. Berry

Institutions: The University of Texas MD Anderson Cancer Center, Berry Consultants, LLC (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2551534988

FWCI: 0.18

Cites: 1

Cited by: 1

Related to: 10